AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.

Promising new data on blood and bone marrow cancer therapies that re-engineer immune system cells are convincing more doctors of the validity of the approach, according to Reuters interviews at the world’s biggest annual oncology meeting.

An experimental Merck drug succeeded in preventing clinically serious cytomegalovirus following bone marrow transplant and was associated with a lower death rate compared with placebo.

Pfizer’s cancer drug Bosulif was found superior to Novartis’ Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer.